1. Search Result
Search Result
Results for "

S. aureus ATCC 29213

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Peptides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-150331

    DNA/RNA Synthesis Bacterial Infection
    DNA ligase-IN-2 (compound 2) is a potent LigA inhibitor and inhibits the DNA-independent autoadenylation activity of both full-length LigA and a truncated enzyme, LigA:AD (IC50=29 nM). DNA ligase-IN-2 effectively inhibits the growth of Staphylococcus aureus in vitro, with MIC valuse of 1, 1, and >64 μg/mL for S. aureus ATCC 29213, S. aureus ATCC 700699 and E. coli ATCC 25922, respectively .
    DNA ligase-IN-2
  • HY-178949

    Antibiotic Bacterial DNA/RNA Synthesis Infection
    MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
    MRSA antibiotic 3
  • HY-169571

    Bacterial Infection
    Antimicrobial agent-38 (compound 10) is a potent inhibitor of methicillin-resistant S. aureus strain ATCC 700699 and nonresistant strain ATCC 29213, with MICs of 32 and 64 mg/L .
    Antimicrobial agent-38
  • HY-161827

    Bacterial Infection
    Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively .
    Anti-MRSA agent 14
  • HY-P3349

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]
  • HY-P3348

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]
  • HY-179059

    Bacterial Reactive Oxygen Species (ROS) Infection
    Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections .
    Anti-MRSA agent 40
  • HY-172390

    Bacterial Infection
    Florfenicol-propanoate-piperidin (Compound 1) is the derivative of Florfenicol (HY-B1374). Florfenicol-propanoate-piperidin exhibits antibacterial activity, inhibits E. coli ATCC25922, Salmonella CICC110420, S. aureus ATCC29213, B. subtilis CMCC(B)63501, E. faecalis ATCC29212, S. suis CVCC606, and Haemophilus parasuis with MIC of 2-8 μM .
    Florfenicol-propanoate-piperidin
  • HY-168729

    Bacterial Infection
    Antibacterial agent 256 (Compound C09) is an inhibitor for type I signal peptidase (SPase I). Antibacterial agent 256 inhibits gram-positive bacteria, that inhibits S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1 and S. suis P1/7, with MIC of 1-16 μg/mL. Antibacterial agent 256 exhibits cytotoxicity in cancer cell HEp-2 and Caco-2 with CC50 of 14.65 μg/mL and 21.93 μg/mL. Antibacterial agent 256 exhibits a hemolytic activity on mouse RBCs, with an HC50 of 13.29 μg/mL. Antibacterial agent 256 ameliorates the MRSA skin infection in mouse model .
    Antibacterial agent 256
  • HY-180767

    Drug Derivative Bacterial Topoisomerase Infection Cancer
    Azithromycin-amide-C3-amide-quinoxaline (Compound 5f) is an Azithromycin (HY-17506) derivative and antibacterial agent. Azithromycin-amide-C3-amide-quinoxaline inhibits topoisoisomerase I with an IC50 of 120.7 μM. Azithromycin-amide-C3-amide-quinoxaline interacts with 70S E. coli ribosome with a Kd of 0.8 nM. Azithromycin-amide-C3-amide-quinoxaline inhibits bacterial translation with an IC50 of 0.7 μM. Azithromycin-amide-C3-amide-quinoxaline shows antibacterial potency against S. pneumonia ATCC 49619, S. aureus ATCC 29213, E. faecalis ATCC 29212 with MICs of 0.06 μg/mL, 2 μg/mL, 0.5 μg/mL, respectively. Azithromycin-amide-C3-amide-quinoxaline exhibits anticancer activity against prostate cancer, colon cancer .
    Azithromycin-amide-C3-amide-quinoxaline

온라인 문의

Your information is safe with us. * Required Fields.

호칭

 

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

 

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: